Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of APL-2 versus eculizumab in anemic patients with paroxysmal nocturnal hemoglobinuria
NL-OMON46308Phase 3Withdrawn
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing APL-2 with Eculizumab (2 arms). Primary endpoint: Change from baseline in hemoglobin level. Planned start Aug 2018; status: withdrawn.
02
Drugs
pegcetacoplaneculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NL-OMON46308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46308.